-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Fw7kHdKFvY9Qy1gvqky4v8mNE0+OijEJBdsWHDjNtevgvOi5CGtDIHlVxRXRZmZz
 csUlkih3zPEEKKHFHIUdcA==

<SEC-DOCUMENT>0000950144-08-006629.txt : 20080822
<SEC-HEADER>0000950144-08-006629.hdr.sgml : 20080822
<ACCEPTANCE-DATETIME>20080821215553
ACCESSION NUMBER:		0000950144-08-006629
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080820
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080822
DATE AS OF CHANGE:		20080821

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		081033226

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g14847e8vk.htm
<DESCRIPTION>GEOVAX LABS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>GEOVAX LABS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): August&nbsp;20, 2008</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in Charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>(State or other jurisdiction of</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Commission File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(IRS Employee Identification No.)</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>incorporation or organization)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1256 Briarcliff Road N.E.<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306<BR>
(Address of Principal Executive Offices)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(404)&nbsp;727-0971<BR>
(Registrant&#146;s telephone number, including area code)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the Registrant under any of the following provisions (see General Instruction
A.2 below).
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4<SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> under the Exchange Act (17 CFR
240.13(e)-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;Registrant&#148;) from time to
time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the Registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the Registrant or the Registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the Registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the Registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the Registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<!--TOC-->
<!--/TOC-->




<!-- link1 "Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers" -->

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD align="left" colspan="3"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; <BR>
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective August&nbsp;20, 2008 our Board of Directors appointed Mr.&nbsp;Peter M. Tsolinas to the Board
of Directors. He has not been appointed to any committees of the Board of Directors. There was no
arrangement or understanding between Mr.&nbsp;Tsolinas and any person pursuant to which he was selected
as a director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Tsolinas will participate in our existing non-employee director compensation plan.
Accordingly, he will receive a grant of options to purchase 1,320,000 shares on the date he is
first appointed as a director and compensation for Board meetings he attends. If he is appointed
to committees he will be eligible to receive a pro-rated portion of the applicable annual retainers
for such services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During November&nbsp;2007 and May&nbsp;2008, Mr.&nbsp;Tsolinas participated in private placements of the
Registrant&#146;s securities, pursuant to which he purchased a total of 7,096,774 shares of the
Registrant&#146;s common stock for an aggregate purchase price of $1,100,000. In connection with these
transactions, Mr.&nbsp;Tsolinas also received warrants to purchase an aggregate of 14,193,549 shares of
common stock with an exercise price of $0.33 per share and expiring in November&nbsp;2012 and May&nbsp;2013.
Other than the purchase of our shares, Mr.&nbsp;Tsolinas has not been a party to any transaction with us
that we would be obligated to report pursuant to Item 404(a) of Regulation&nbsp;S-K nor has any such
transaction been proposed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;20, 2008 the Registrant issued a press release (attached hereto as Exhibit&nbsp;99)
announcing the appointment of Mr.&nbsp;Tsolinas to the Board of Directors.
</DIV>
<!-- link1 "Item&nbsp;9.01 Financial Statements and Exhibits" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following exhibit is filed with this Current Report:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;99 Press Release
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 "SIGNATURES" -->
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly
authorized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: August&nbsp;21, 2008
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>g14847exv99.htm
<DESCRIPTION>EX-99 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit 99</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g14847g1484701.gif" alt="(GEOVAX LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 60%">Contact:<BR>
Melanie Nimrodi, Media Contact<BR>
312.546.3508<BR>
<U>mnimrodi@frbir.com</U><BR>
At the Company:<BR>
Robert McNally / Jennifer Nelms<BR>
404.727.0971

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">FOR IMMEDIATE RELEASE
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GeoVax Appoints Mr.&nbsp;Peter M Tsolinas to its Board of Directors</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ATLANTA, GA, August&nbsp;20, 2008 &#151; GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta based
biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human
Immunodeficiency Virus) and other infectious agents, is pleased to announce the addition of Peter
M. Tsolinas as a member of its Board of Directors. Tsolinas, having supported the Company through
private investments, now joins the Company&#146;s Board to further his contribution through his talent
and three decades of business and banking experience.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Tsolinas currently serves as Chairman and CEO of TMA Group Development Corp., a Chicago based
real estate, architectural and development firm. As a real estate developer over the last 30
years, Tsolinas has built a successful network of companies involved in architectural, development
and construction of commercial, industrial and institutional facilities. During that time,
Tsolinas has participated in joint ventures and partnerships with Lincoln National Life,
Commonwealth Edison, and ADP Corporation, as well as individual private investors. Further, Mr.
Tsolinas has achieved additional successes through his personal investments in the real estate and
banking sector, where he served on several bank boards from 1977 through 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;As a substantial investor in GeoVax, I am honored to join its Board of Directors to further assist
the Company directly,&#148; said Tsolinas. &#147;I have been truly intrigued by Dr.&nbsp;Harriet Robinson&#146;s
scientific efforts and dedication to help humanity and I look forward to continue supporting her
and the Company in their quest to cure the HIV/AIDS pandemic.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Tsolinas continued, &#147;With the exceptional trial data the Company has demonstrated to date, I
envision a very promising future for GeoVax and its shareholders. I am personally humbled to be an
integral part of its success going forward.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Robert McNally, GeoVax&#146;s President and Chief Executive Officer, commented, &#147;We are very pleased
that Mr.&nbsp;Peter Tsolinas has agreed to join our Board of Directors. His substantial business
experience will enhance and complement that of our current Board members. Peter has been a
faithful supporter of GeoVax and we welcome his further contributions to our success through
service on our Board.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Tsolinas earned a B.A. degree in Architecture with a minor in Byzantine History from the
University of Illinois. He has been a speaker and panelist at numerous Architectural and
Development Conferences and is a member of the Chicago and National Chapter of The American
Institute of Architects, as well as a corporate member of NCARB and NAIOP. He has been engaged in
several philanthropic projects and currently serves as Chairman of the Stewardship Committee at St.
Nectarios Greek Orthodox Church.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Geo Vax Labs, Inc.<BR>
Add 1</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B><I>About GeoVax Labs, Inc. </I></B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and
commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other
infectious agents. GeoVax&#146;s AIDS vaccine technology is the subject of 20 issued or filed patent
applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired
Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become
infected. GeoVax AIDS vaccines also may be effective as therapeutics, treatment of people already
infected with AIDS virus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax&#146;s core AIDS vaccine technologies were developed by Dr.&nbsp;Harriet Robinson, Senior V.P. of
Research and Development, through a collaboration of colleagues at Emory University&#146;s Vaccine
Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention
(CDC)&nbsp;and GeoVax.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine
Trials Network (HVTN)&nbsp;based in Seattle, Washington. The HVTN, funded through a cooperative
agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials
program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided
additional support to GeoVax AIDS vaccine development program with a $15&nbsp;million IPCAVD grant
awarded in late 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Safe Harbor Statement: All statements in this news release, which are not statements of historical
fact, are forward-looking statements. These statements are based on expectations and assumptions on
the date of this press release and are subject to numerous risks and uncertainties which could
cause actual results to differ materially from those described in the forward-looking statements.
Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and
manufacture these vaccines with the desired characteristics in a timely manner, GeoVax&#146;s vaccines
will be safe for human use, GeoVax&#146;s vaccines will effectively prevent AIDS in humans, vaccines
will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required
capital to complete vaccine development, there is development of competitive products that may be
more effective or easier to use than GeoVax&#146;s products, and other factors over which GeoVax has no
control. GeoVax assumes no obligation to update these forward-looking statements, and does not
intend to do so. Certain matters discussed in this news release are forward-looking statements
involving certain risks and uncertainties including, without limitation, risks detailed in the
Company&#146;s Securities and Exchange Commission filings and reports.</I>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">###
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g14847g1484701.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g14847g1484701.gif
M1TE&.#EA)P$R`.8``"ILF&R5MR^%M,37YRYZIP=5>?_^^;G3YY7)YRF4QQ18
MA.3L]NOT^@EWK?3Y_:7$VI>ZTXJYU<GF]?[^_M?B[DN8Q[3'VZ;+XQEHE'BG
MQ_[]]!16?&FEQ_'U^T)XGH>KR-';YFJ=PK3-XMSI]$&"J__^^Z6ZU%BDSPAE
MEZS2Z56&J9.TSEN4N=OD\=+D\0Q;BG6@NU6+LHFEOT6*LQ5AC'RUU@EAC(>S
MS@-<BI;!W`Q4@@-9@?G\_@Q:@./R^P14@05.=;;9[NKP]VBSVRA@CY*LPW*K
MSP9=D??[_<W@[=SL]];H]15/>+KA]/[\_?S]_L+=\!98CDB0O`U4BFJ[Y+G0
MV_WZ_-KP^A=/A62LT@96B/[]_AURH/SY^^3I\A95<"I1<GBPSL;.WM'K]_O\
M_H6_W^[W_?#R^/O]^PA@?>/Q]V*/J`Q)<`U3;A9(;5V=P8FNSM;?[:/1W;_0
MXPQ/@")BA/?Y^^[W]X"<N_+L]:B_T)W3[K;#U/KW^P9+7O___R'Y!```````
M+``````G`3(```?_@'^"@X2%AH>(B8J+C(V-(`.12(Z4E9:7F)F:FYR=GI^@
M@@-<"G4ADZ&IJJNLK:ZOKT@S!1LS7;"XN;J[O+V5'1A342F^Q<;'R)<,+B![
M951#0P$!+#$JUR39VMLQW3$LU%E#91=!4&H.AQ!:&RS)[_#QJD\=0@LM`SDU
M83`L,P1<B-`H10.#C1<]VO30TF-##SH]?OS8\0-(@0([@.S8H0/C1AP;C^`X
MJ.,%#2Y<!,2XX8`$'05Z6BSH\$2>S9LX"3UQ("0)@C(96`@@`$#@$8<*=.CH
MH:#`TA]U:/1XH8"&50Q@Z@#@0F"H@*$$2'PET!4E%ZL;!O8`T@-'@1\8_S/(
M>;'!`P(B!&)DN%%FSH(S=B;D'$P8UH0Q%U9P:&!#BY:-.U[H@*M@`Y8H3**\
MF((A[S0887(<@#)"B)5!@@\Y4<1#B(L!0?9$@,&!A8H#*-I,61&@`$(F/6A$
MP8)AA@P(4'@47LY<TQ8?0<)(X7+$L5N)'A_B:&B2RQH\>,H$D>!C=:K4@[8(
M<L#`AXC';"Y40/'BB&0=7XY\`<.$Q@P8.:2`7G,$%BB('1(8$0,&1XBTT6-3
M_*`%2"_@T!D'15R0A!=G.,"#>9F`J(D9+!30!@Y/V%%/'(D5$4`"4]0115HO
M&$0#`0&4$8>!/-HT@1D+I)"!`%Q@\,(.;R&)Y/]$=1#``AX15"&3$*@D,B`A
MZB&"7I9_<$E("85,L(4!`V#0@PXK$)*:$V;X0$$5.12QA@=$8*#`%"^@@`$`
M(400AQ<U]2CH+CQXD4,%`J!P!$8_Z$`112]$04((-0RP@`-HI'<E(>9YJ:8@
MIQVBWI:H;8K:'T;TD$847CCB@!<@S`&#"E'A>80-`!#PP0`=F#KHKYU,@,0`
M'.#`!)YMT('#%!AM@$,#+%2AW"HB"E("F)@8,,AJ)7#Q!1,A>%J)!$.H@`%P
M/>R``Q<Y!!$HL/!RL@0<`FB!14=TI($#$$`<\0,7(8C0@2(=C-#"P0@?'.@6
MZ!E0PJ;8*N*`!&,L88;_(SX0H<4+$'2BA!$>'!'%%$S@@((`%MAA@`;7&N"P
MRR48,(',+O^A@<,W_U&S!AKHK.W.VO*LLP8S_QQTSSG#O++/+[M<L\,M.QUS
MSCT[S?3-,1M=0M)'^VPSRUPSO3*8#OL\@=!/W\SUU#HG$L0,FBFPPP8;8/3%
M"R\0$$(0#IAJ`!(1L,!%%#843A_>F\V@QA_O$E)S(3(/$OD@#GP0*1%)7)N:
MJ1QLA`$#71HB+FJ>;H&$%R+`@,$&3+!Q!`$K5!GO[(J<H0<+-$R!PP\O6!<9
M!BP,0&4B/%@@P'836<0[#B\TQJP8@JQ6]I>"&#"Z(4IP@:01TQ9RK2!/</'2
M_P"^#A+Q]W],,*#Z@G0QP@HD$+&#%C;HW4+CM.?_AP0JT%"A0V[!2`&`!X);
M)&(+#H``!N8V(0)<0P5K4$$,UF"-*$#//.7SWLS^H#EM,2X'--@!"19@OK8)
M9F8'L$$;2&!`0TP`@^G#EA/4=SU!3$`(Q,)``;0P!0)<0';Z@]<$+-"@`O2@
M`%/0`1-V&(4<=$\14#@>D@10AC-4:PL:8-@!7)`^G6$+:QX<1,\B9@B6_2$`
M0'A!!-)G*A[,(#,/J(03T">(+(7Q$`L(`1W:\)8W!":(\>H``!C"/!Y.10=1
MJ($C)@"'W6F!!B)PX8`<8`=&:,L*-33$>W:0!5\]0?\)==@!$2A@)?6\S!'7
M4P(),``2&Z2@#X#\U1,L0((V,*%"3-E`%`K`A0%X:@)@NIG4H&"F'Y!@"1DL
M!(C(:,-#!$URA'"`#@%PA>I9S0`,J$#=UE!)*W51/1$C6LQ*$*HNJL8!(R"!
M#G`0!18((9:".L"Y[G1$IE3E!DE0Q`G39X<*:($)&,@GEG3&K9C5<0O@E-P&
M[QC,AW&0@PZ=7`AX5X.+L?&$57C!6P1D)?Q5[Z'?;!L;$Z&$&""1#1$@`SQY
MQ`(M)`4+/0B.`GH0AG0P`J%_2()4%)"!*W*02]C"*33OX`(7@(Z#TYN<(#JP
M!`DH`0VI20(*UC4'0SC`"#C_^`(&!B:(!00A!2D@81P><($Q_&$$%[B`'"ZP
M.$.8(0AJW<,":CB"&>R.`*U::8$&DH:-[7`*0/"`[(`IN3L*8@4,X<((%F%8
M0I@!`E+`0!2(H!4.C&!3$TA"9&EPA!O50`WJ8X%$I&`(%XBO`$7X0P=2$-E;
M644`(A``#;#`MP@0X`<VF(%%!V$&$MB'!&4`HB'BD(8"X.`">B70!+#PA1XP
M(0U@8(,"F)"FT*%F:=;RX!9@H`,:G."HI0)I]9R`-9]!P']R4X`"L#`%(PSL
M9S-C@!26M9V-T``"2OA#&-1%A%N4S0`/.`@0DB."!APR#>JE`0M*1`<9_.$,
M%B!"_V8&X#4T0,$&!;"!!101J)9(I&/);<XM&;*4J4Q!`LUDA+`$\`,BF+40
M9H!"$YH0A!DW`0HI\`'[T!`#X7Q!`1AH``V4V`,5Y/4/2`@#%_BU`QLH*B08
MB$,2N``28A#B#4@"`!*,@`+':`$%7$!!#]R`-P5$`0;@6P&>``#B/T0``R\Q
M@D<1@8#;MCG$A0&`+E\`TR,J8&$?5=,D";`#`BR6$$(@`0U0P.A&+QH`%/[#
M"I)2!Q4\H`5+$(,)`,`$'00`Q7_(@0V^8$P+4$`)<0C#('7`A23`@"TQL.D?
M?*##(Q0AA5K0@0<N<.HE7(``T[4,F@7!@S5L@"'$2(*1"O\0@#,L0DR"4,,,
M>G``/#,G!)51RDR#P]4L@>G;#Q.,01U``"!PH05J2L%#@%"9,^E@`W1@0@;^
ML``BZ*`.?'`V(5P`@.[&8`)W((!O2%#-03SA`'6(:0;F@`.3Y5-F-S@2%[Q`
M@BEL@`-'%L05",`Z<.V;`*WS0!+6\&XB<)$220C+.ZU=F"5X8`HQG0H6CA!I
MP336JO4"`#()<0$,>&`;V?#`#J;``358``<;6.,A+K"!-F#@##E@U@M(&*84
M+-`#2Q``OVZ@'!YH70$'4,*,6,"^0@R@#C;`0@C,3@-GK>X+48BDBF?&@_E$
MFN6$X0$<`("#C4W!#06HKC[1(XO_`M1!!/H6Q`$0`$P/_N@`"G!#")10@3;H
M``2(&`$1IJ`%(>!!B21X(FIFH`4,0($*`)A"#)SM@R^PV@$(:(,-UK@I)1!@
M('A0I@<4T(;A[```/JA$]CS`5;P/9@)/``$*"O`%A^R`!BU(9B%6\`,<&)H0
M9Z@)>H`Y`!S0(00I:,`4/`#>/PS@`Q^`PPKZ_040H+$'PW9A#H!`@Y2I``@8
MF,,$<M"1M6<@1G<7)@'@>FNG)G$@!3O@!DQ``OFE8H+``&]0!N5G?,='`3-0
M(3/U`B1P<M_6-@YE+8+@`C3`/&'@*R`R!R]`!V]@`2C`!.0W""(@%4>0%$J!
M!4F@`DY1_X"2HQY;<`$_T`-Q!`5P$0)F0`!T8'I_4`0Z0`0[@@@P@`5J9P@,
M4`;_Q`12\&+/-@%04`/Z1X$$(@09```V@`,*D#<K@`;,]"F"@`0QD&4GIPC=
M!RY!(`!M0`3H)@A%4`!IP`1@T`,SP@5JT!L_\&\@2`@9\$B11`9\QP4G0`-`
MP`(#`P$6)W=6Q0),@`4!$"8?@`)*I$LDL'*U0P$7L`1>:"`3@%8$@'21$0(+
M0%B(@"UQ@`&-<GW4DUW=5P`AX`,0\!9Z<$(KL`868`(6H`=ZP`?H!@$:A0%M
MI1,#D(H`@&+[5WV[`P1R)P%]17;B,@<#L0&92`@6,%,[X`%2L?\#++!;HM,!
M+N`%TE>*[[`:`R(!"\1G3,`2(&ASI_('#G"!$F$$LM9%8*(^W:<#(3`!`[`!
M"J`"Z3`!10`"9V,(VJ@`6O``C:,!9H"`.Z`"7"4!+S`1D4%*Z5,'^(=,U7("
M^(&)A(`$;^!]<8>#,]<$5E(M[+@<S'0&#T`"=?`8)/``2:`M'RA>.44"1_0#
M,V`"+D`&V!)&`_`"0+!V#B!T6L`"8D`&?3!G@A``6N!T#^``V.("6`82$EE'
M)'`12UDE6+4#&+`"Q><`-=!VZ@4#Z&$"-,`$?I`F9:(#6J`"5!<]0B`$_1B3
M,@E-I3(&$+`@!0``80`%F>(]8$(/$9?_+CJ``BKP!APPF5G``490`2E8@+'(
M%#2@`D9P`Q]P`W`PFNJ77TG@`6]Q!"0PF6_`!;GV`QS0CQ'@9>3#6Q[`#EJP
MFASP!B2`-W0CD(/0`@#0!IUY5`_@`73P`BP`!1)P`*-!`0Q0$PL@`J0H"$H@
M`G=8"7#P`"JU"8<QC"(P@8[P`!D@>HTP`2)P``/#`\Y9?*G@`#EP`X*12>VC
M,W:48J9S`$4``R1``!P@`BZ`AM9">!#@`0B!)$E!!W0P-W3S`DS0C?O'!0:)
M.,W3<(54`4B0?!QP'T=`!T!`!_YFCG_@`K<%`-UD+0,P`Y:Q`<VS&<0AH3U`
M6D]P!BK`.BP0_WQK.`(T8$0"$(%0T#@7<`3AHEHQ@`+(50D3(`!%`).68`%D
MX0$$4&V6\`09$`/=*7SU0XI0<#(-J`H,P`)H-@<9P`>)("(#DH9_P"8#D`%D
M,0-L-6<=``$5$&:W4C@X4*?Z0HM_T`(AX`$&`0:=I2@HH`!.E@1/H#YSL$H[
M@`+U\P8N`),\<`,XH'2%T`%S,!UIP#MU$`-)8`&IAP-+D`,$<!`>D'B#\&MA
MX`)]*0@,)P!]<P%:H%LC``(NL')(L`0@0`'O=`<4D*M_<`=0(`1V@'EJ``*@
MN`"Y&BH,``(@,`)/1!8,X`!+X&P+P`Q4UP&Z"@)*L`0#0P9+L`!(H/^K?Z`$
M(\``<:`&W>D#(!`'#-`"_3@`3SD).:""/%"K72($B^4`NOHG$W`&24!U#M`"
MN7H&R$<!9W`&()!7=I`$/N`#=A4&KM%-^&I##.5!V%(^/I```'`"+K``-?$P
M9+0$69``)%NR)IL`<E`(#A`!7V&R+9L`P34(2(``)=L$OC(!*2``76H(3[`'
M%4"R"+"&`Y``!'"R4FH)+O`O5H0'-&`"(W`\#1`!MQ`'`M``#8``2&`!"=``
M"?`'(I``K]$`9Y`%-%`&Z_$&+\`%F$<&)B`2`E!\5L`%'M`W:[@8.'`*7IL`
M$>!=4H!B!S@$8U`!4#`!)W`".8`"84!"=E#_`U:+`!P+(E6@`\,F`Y*[!0D0
MM&10!D,P`4$@!0C0`$:`!%D`NH+1!`)0``EP`?0@`'N0`PUP`C4A`170!"'0
M`#N0`$,P`Z3T!!%P`J!B/F$4,?3)`\VY!PB0`A(@`>+9)70T>-O"I*)C"2_T
M,P.%"66G"$*P`5S@`U#`!0C``$N0GJ,*!2(``"JP`C=P`*(5`Q``!T\P510`
M`3^0`&$@`"]@!E;P<[+R`Q?P`!AP`0,``70K"#"``P+P`'9@!QQ``CD@`K#C
M`'#P`E(0!D;P`\'%`E%Z`30`!2ZP2OTP!3.`!B%P7Q!``%&P(UE2`73`!5(P
M`US0!@]``=2H6B3`_P)U9P-2<`)L0`!O$`-:P$4M\`!5P`4%``))@`,SD`4L
M\`*#&P$`T`(0$`4`L`(7@`)ZL`50H`!RX"D&I29D]#"9Y`!C(`%7L`1W0)7&
MD"4-(U+G>3W7FPAF0`I+$`(DT`%.``(YD`$D@`,#@,$,(!A0(+DK9P8OT``+
M\'\2\`1EP`1F4`9`8`0B<`-TD"$8``,N60@+``-U\`(7(((AD%8X<H`$D%^?
M*P/$9`%DH&H+4`,H$``\,`"Z=G9X,$-O0`/+^`=#)@5O@&TZ,%8[0$(M4`<K
MP``O``!Q,`(_(`!J<`!`X`*9E0-&4&YB@``Z,`!.H%-A%0`$@`1*H'H3T/\!
M7%`$@>@!T[)/]^C%6+*.C*,)T,L)ZZ/.8=(E7#(FVZ)/,8`%#P``00@`1N"I
M-J!*,3`M%@`$<9`:0:`#>+```N`!@O`!6/`'#>!I)U`!>X,$)H`!*&`!5_($
M-5``+"`"Y%@!$WT!"(`#>'`:2S`#>*#'/#`!`4`"#J`".%!M#[`#`6`!=$"F
M?R`%'O`N"P`$#<!%:L`$#:`&1=``E?0`42`!*5``;\``>T`'"&`&$8`%9E"^
M,"`"1&`#$J!JZ:#!<;`'`)")5.A@$T`"4A`!1%!5O[L^-H/.FB(Y:*H+2E4)
M]+D(Y710(U4^$X`'!0`ME80'`#`"!U#,#A`#<>?_!0L`!5K`!0?`(7KP`SG0
M`D20!8(0`P#P!U3`!A90#S7A!0PPKV_0/2;@!2.@1Q^0!$=P`0S``$(P`1SP
M`TJ7!S#`%5S$`!X0`@P0$.AF!#D=!%'P`4+PC>X`@UA@`N]T`$R```X@`S80
M!W%``$?P!S+P`Q#P!#!`!!T"`P`P!@L]`B)@`R/$T^E3!$30`49P!&L4`B\@
M`P-S`C;`!3/P+@U#SX"Y"$YPU]:["GY#1_!L"'-D78BP`NH"8H<K!<>C90C`
M2@T0:RI`/RA@`D8`!`,P!PH0M'_@0'_``W7`B)_X!XS891L&*D'6`#^``6/0
M`2J``A4@TOD(!$$P"#=@_TR30-E%H`08<-Y_L,<@H.)'T`!%$G]_H`=M``*G
MH0=:4-`F\)BXP@5G%)%(H`+;S``S$`-FP&450``HX`$+X`%K\`=V$`(`P`,!
ML`'(]0%?IDA[P!""EZ8;E`@14S1(Q<8]Z0EE)[RO2%B1`TSJ$V[AY9-M0Y\,
M0SJ*J3ZFD@00L`)M%:>[<@.JZP`BD`$90#Y"<`-&``<C(`<R<`8N<`,6!0%5
M(`@@$`8<L`(S%`$A\`$6D)A_T`4/8)EZ`&I*\`&6.0!(D`,?`%X2<`.15NE)
M<`8K<-U/\`#?.Z(K\``/0`0F0`AQ4`1<-0`KX&P=`)HB(`)Q]``KH`3#_@`3
M8/\'#W``/Q(!AYD#K&T"4+#A*<#M#W`#B^,`#_`!514$!:`"=\`EZL.3%!N\
M;)Q=:M+.FI#7=72F@&XE!C!#A#77T(8(HQ)NUU("#-/P(W6>`GY`F(!3^EUV
M93?HA9!)\5L%%Z`"'H!YWD0)"7\(R*<(#+,`.?`5;%W/]5B+)<3&XK9/,F-0
MFC,S#\.3W]/P#N.*K?Y0?&Y.0K](0.5-[4Q#,N/S/C_T^C3Q3>\*:FSO_PT%
M,Y`K)"!0N2!]!P``).`%OR3T<PTY,;/T__ULWJ/Q5B!NCB/Q0\\R2U,V+Z3P
ME"!4^*W&-Q7/K-`X-WO.=;0+821]UY/V8?]0/9/G6*)2WXL`)DY@6(,/47/.
MYU=R/HH`\"Z?"#T?\:CD""""^-8[SUJR.64?"AH/"C/T;8T%LH:_"C>7&HVO
;"(,?]FI/1C-#]M)WO6^<^88!^,G`^880"``[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
